ASH 2020 | First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma. MEDI2228 is an antibody-drug conjugate of pyrrolobenzodiazepine, a DNA crosslinking agent, and a monoclonal antibody directed against B-cell maturation antigen (BCMA). Efficacy was demonstrated at all doses and a maximum tolerated dose of 0.14mg/kg every 3 weeks was established. A unique safety profile was associated with MEDI2228, including photophobia, skin rashes, and edema. Although mitigating the toxicity of MEDI2228 remains a challenge, patients who have been heavily pre-treated could benefit from the therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Amgen, Bristol Myers Squibb, Takeda, BeiGene, Janssen
